Advanced Skin Cancer Victim Cured By Miracle Drug

Miracle drug pembrolizumab seems to have a cured a man’s advanced skin cancer

A new miracle pioneering appears to have a cured a British man of advanced skin cancer, after he was told he only had months to live.

Doctors are unsure whether the treatment had led to the outcome however they had no other explanations. Results from an early stage trial of this specific drug indicated that it might offer a potential “paradigm shift” in cancer therapy according to the patient’s consultant.

The drug called pembrolizumab, is the latest in a new generation of treatments uncovers the cancer and stops it from shielding itself from the immune system. The drug was tested on melanoma because the prospects for patients with advanced forms of disease are so bleak. Of the 411 patients that took part in the trials, just under 70% are still alive one year after starting the treatment. At the moment current survival rates for untreated patients diagnosed with advanced stage four melanoma are just 10% for men and 35% for women.

The “cured” patient was a 40 year old man from London. He has undergone six months of treatment with pembrolizumab. Doctors were left in shock as after 3 months of the treatment, his tumours had almost disappeared. Since then they have showed no sign of return and in fact have shrunk even further.

His consultant Dr David Chao, from the Royal Free Hampstead NHS Trust in London, said: “We cannot say for certain he’s been cured, but he is doing very well.”

Results from the trial were presented at the annual meeting of the American Society of Clinical Oncology in Chicago. With more work being done on Cancer research more and more news stories have been appearing in recent weeks, with Cancer Treatment Elotuzumab Given Breakthrough Therapy Designation by the FDA and GSK investing money into Adaptimmune. 

This all shows that Cancer treatments are moving forward and fingers crossed that the future of Cancer is under major threat.

Alex Carson

PiR Resourcing leaders in senior life science resourcing. For more news and information, you can follow us on Twitter and LinkedIn 

Leave a Reply